BRIEF DESCRIPTION OF THE INSTITUTION

The Medical University of Lodz (LODZ) is among the largest state-owned medical universities in Poland. The University was established in 1949 and consists of five Faculties and three divisions.

  • Faculty of Medicine with the Division of Dentistry;
  • Faculty of Pharmacy;
  • Faculty of Health Sciences with the Division of Nursing and Midwifery;
  • Faculty of Biomedical Sciences and Postgraduate Training;
  • Faculty of Military Medicine, with the Division of Studies in English and the Division of Physiotherapy.

LODZ covers all areas of medicine with its own four teaching hospitals and numerous clinical departments within different hospitals. LODZ researchers conduct extensive basic and clinical research, accumulating unique knowledge regarding clinical trial performance.
The Medical University of Lodz has reached the leading position in the following research areas: immunology, molecular biology, genetics of haemostatic disorders, oncology, hypertension and endocrinology. LODZ has been steadily increasing its potential in gaining funds, both for basic and applied research. LODZ conducts extensive research collaboration with such foreign research centres as:

  • University of Alabama at Birmingham, USA
  • University of Texas USA, Health Science Center in Huston
  • King’s College London, Great Britain
  • Medical University of Vienna, Austria
  • Charles University in Prague
  • Odessa National Medical University, Ukraine
  • Radboud University Nijmegen, the Netherlands.

PREVIOUS EXPERIENCE RELEVANT TO THE TASKS

LODZ participated in 5 projects under the 5. Framework Programme (including a coordination of a Centre of Excellence in Molecular Medicine), 10 projects under the 6.FP, and 18 projects within the 7.FP, including two coordinations (ABC – a small collaborative project, and Healthy Ageing Research Centre, which is a RegPot). The university also acted as a partner in two Public Health projects, and numerous other bilateral research collaborations (including Polish-Swiss, Polish-Norwegian and Polish-Taiwanese Research Projects). LODZ also participated in several R&D projects co-financed by the Operational Programme Innovative Economy (1 coordination in sub-action 1.3.1) and in numerous projects financed from the Polish state funds – National Science Centre (LODZ ranked 2. greatest NSN beneficiary in 2013).

DESCRIPTION OF ANY SIGNIFICANT INFRASTRUCTURE AND/OR MAJOR ITEMS OF TECHNICAL EQUIPMENT

Medical University of Lodz is in possession of well-developed infrastructural facilities. The university now occupies 84 buildings with a total area of 135,084.23 m2. A pre-integrated computer system was created for administrative, teaching and research purposes. The University has a well developed equipment base necessary to conduct advanced scientific research.

Since 2008, the university research teams received several grants for R&D projects, which in some cases have resulted in the commercialization – either in IP sale or IP licensing, granting of European and American patents, or the establishment of start-up companies and spin-offs. LODZ has its own Centre for Innovation and Technology Transfer responsible for the internal politics of IP and external relationships with entrepreneurs. LODZ is also involved in BioForum - the Forum of biotech companies from Central and Eastern Europe (www.cebioforum.com, and it is a shareholder of BioNanoPark (www.technopark.lodz.pl) , and a partner of many research centers, including BIOMED and BioTechMed. LODZ strengthens its position through effective management and allocation of internal resources. Since 2010 LODZ has been implementing its own development strategy and providing various tools for its students, employees and partners in order to improve the potential relationships and networking. LODZ is the only university in Poland, which implements the concept of Business Process Management, using the BPMS platform for the daily management of the organization, not only in relation to the administration, but also teaching, research and clinical activities.

The Healthy Ageing Research Centre (HARC) was founded by LODZ in 2011 on the decision of the Rector and Senate to conduct research on various aspects of healthy ageing. Major areas of research cover wide spectrum of topics related with ageing: novel approaches to improve well being in the elderly, pathogenesis and prevention of neurodegenerative, respiratory, kidney and cardiovascular diseases of the old age and molecular basis of ageing.

The Centre for Innovation and Technology Transfer is a university-wide unit fostering collaboration between scientists and entrepreneurs. Scientific studies are also supported through the establishment of the Central Science Laboratory " CoreLab " to facilitate access to modern research methods with the use of specialized , high-end equipment. The laboratory is equipped with test equipment used in genomics, proteomics and morphology.

SHORT PROFILE OF KEY STAFF MEMBERS

Tomasz Kostka: Professor, Head of Department.

Lukasz Kroc, Physician, PhD student

Agnieszka Guligowska, MSc, nutritionist, dietitian, PhD student

Joanna Kostka: MSc, PhD, physical therapist

Malgorzata Piglowska: MSc, PhD student, experience in public health and nutrition

Kinga Zel: MSc, financial manager. 

LIST OF THE FIVE MOST RELEVANT PUBLICATIONS AND/OR PRODUCTS, SERVICES, OR OTHER ACHIEVEMENTS

  1. Kostka T, Para J, Kostka B: Cardiovascular diseases (CVD) risk factors, physical activity (PA) and plasma plasminogen (Plg) in a random sample of community-dwelling elderly. Arch Gerontol Geriatr 2009; 48: 300-305.
  2. Kostka T, Jachimowicz V. Relationship of quality of life to dispositional optimism, health locus of control and self-efficacy in older subjects living in different environments. Quality of Life Research 2010;19:351–361 DOI 10.1007/s11136-010-9601-0.
  3. Borowiak E, Kostka T: Comparative characteristics of the home care nursing services used by community-dwelling older people from urban and rural environments. J Adv Nurs 2013 Jun;69(6):1259-68. doi: 10.1111/j.1365-2648.2012.06113.x. Epub 2012 Aug 5.
  4. Gawron-Skarbek A, Chrzczanowicz J, Kostka J, Nowak D, Drygas W, Jegier A, Kostka T. Factors determining the total serum antioxidant capacity in men with coronary heart disease - The powerful effect of treatment with thienopyridines. Nutr Metab Cardiovasc Dis. 2014 Jun;24(6):e21-3. doi: 10.1016/j.numecd.2014.02.011. Epub 2014 Mar 1.